Stereotactic body radiotherapy with continued first-line PD-1 inhibitor-based therapy as a resistance-overcoming strategy in oligoprogressive hepatocellular carcinoma: A prospective phase II clinical study
{{output}}
Purpose: This prospective phase II trial (NCT06870942) aimed to evaluate whether stereotactic body radiotherapy (SBRT) combined with continued first-line PD-1 inhibitor-based therapy could overcome acquired resistance and prolong... ...
